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Design
Pinak Patel
Abstract
When a promising new chemical entity is synthesized, it needs transformation 
to appropriate formulation in order to show a better and desirable action at appro-
priate site. Preformulation study is a phase which is initiated once the new molecule 
is seeded. In a broader way, it deals with studies of physical, chemical, analytical, 
and pharmaceutical properties related to molecule and provides idea about suitable 
modification in molecule to show a better performance. Study of these parameters 
and suitable molecular modification can be linked to generation of effective, safer, 
stable, and reliable pharmaceutical formulation. Therefore, preformulation study 
is an approach for generation of pharmaceutical formulation which utilizes knowl-
edge and area application of toxicology, biochemistry, medicinal chemistry, and 
analytical chemistry. The highlighted chapter is framed with a vision to provide an 
in-depth knowledge about pharmaceutical formulation development.
Keywords: preformulation, physicochemical properties, prodrug,  
stability studies, analytical profiling
1. Introduction
Discovery of a new drug entity is a huge milestone in science and it becomes 
even more important if it passes toxicity screening as the potential benefits over-
weigh the side effects. The ultimate effect of the new chemical entity depends on 
its availability at the site of action once it is administered through appropriate route 
in appropriate form. So for this reason, a new challenge is offered after successful 
pharmaceutical and toxicological screening that is to transform potential active 
new drug entity into a pharmaceutical formulation. It can be broadly elaborated 
as “a phase which works on study of physical, chemical, analytical, pharmacoki-
netic, and pharmacodynamic properties of new chemical entity and utilize the 
obtained results to design and develop an effective, stable, and a safer dosage 
form.” Preformulation study is there for the multidisciplinary approach and utilizes 
involvement of several aspects of pharmacology, toxicology, clinical pharmacy, 
biochemistry, medicinal chemistry, and analytical chemistry (Figure 1). The 
preliminary objective of preformulation phase or study is to lay down foundation 
for transforming a new drug entity into a pharmaceutical formulation in such a 
way that it can be administered in a right way, in right amount, and on perhaps the 
most important at right target. The secondary objective preformulation study is to 
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provide longer stability to the formulation by proper designing and protecting drug 
component from environmental condition and to evaluate performance of devel-
oped formulation.
2. Optimization of an active molecular entity
Following the successful pharmacological screening of an active molecular 
entity, one has to be sure about the appropriate molecular form of active molecular 
entity. The optimization of molecule is needed with respect to stability of mol-
ecule under normal environmental condition or with respect to enhancing the 
Figure 1. 
Outline of preformulation studies.
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performance of that molecule like bioavailability and stability. To inbuilt these 
virtues into a molecule, efforts are made to optimize a molecule inform of salts, 
solvates, polymorphs, and more importantly prodrug.
2.1 Salts
Nearly half of the drug molecules that are marketed as drug products are 
administered in salt form. Converting a molecule into a salt form is perhaps the 
most widely used approach to significantly enhance the performance of a molecule. 
This improvement can be made in area such as follows:
• Performance (increased solubility and bioavailability)
• Improved stability (hydrolytic and thermal stability)
• Better organoleptic properties (taste masking)
• Increased patient compliance (decreased side effects)
• Modified release dosage forms
There are several factors that are needed to be considered while selecting appro-
priate salt form. The main factor that determines the appropriate salt form is type of 
formulation that is to be developed.
• Mostly, sodium and hydrochloride are the most suitable forms to be used if 
formulation to be developed is tablet, oral solution, or injectable. With sodium 
and hydrochloride as salt form, there is always enhanced solubility and hence 
better bioavailability is assured. For example, the propionic acid derivative 
naproxen exists in free acid form and has lower water solubility and hence 
less bioavailability. When it is converted to sodium salt, its water solubility is 
increased by severalfold and hence better bioavailability is assured. Similarly, 
tolbutamide, an oral hypoglycemic agent has 1000-fold greater water solubility 
than corresponding free acidic form.
• Another factor that determines the type of salt form is type of formulation to 
be developed. For example, when the formulation to be developed is suspen-
sion, insoluble salt forms like tosylate, estylate, and embonate are the preferred 
salt forms.
• Therapeutic indication is another factor that affects the selection of salt 
form. For example, if drug is indicated in the treatment of hypertension, the 
use of sodium or potassium salt is avoided. This is the main reason behind 
development of potassium salt of diclofenac, which is preferred over sodium 
salt. Diclofenac potassium can be given as analgesic in patient with history or 
current occurrence of hypertension.
• As the regulatory perspective, selection of salt form must meet regulatory 
requirements and must be free from toxicity. For example, use of lithium salt is 
strictly prohibited.
• For immediate release formulations, generally sodium or hydrochloride salts 
are preferred as they show better solubility. For delayed release formulation, 
one can prefer low solubility salt form such as tosylate, estylate, and embonate.
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• Increased patient compliance can be obtained by converting a molecule to a 
salt form. For instance, injection of cephalosporin generates the pain at site of 
application. However, when it is administered as morpholine salt, the pain at 
the site of application was reduced to many folds. In similar way, salt form can 
improve the taste adaptability by masking the taste and odor. Piperazine can be 
improved organolaptically by converting into salt with adipic acid [1].
2.2 Prodrug
Prodrug is the chemically modified inactive derivative of active form with 
optimized properties and better in vivo performance. Almost one-tenth of 
the pharmaceutical products are used as prodrug with main aim of improving 
bioavailability by avoiding first-pass metabolism, improved drug absorption, 
and organ selective transport. So prodrug can be defined as inactive form that 
undergoes biotransformation and converted to active form to elicit its phar-
macological effect. Development of prodrug depends on specific property of 
drug that needs improvement and mostly with respect to stability, improving 
bioavailability [2].
In recent times, science has moved to “cod drugs,” “hard drugs,” and “soft 
drugs,” where cod drug consists of two pharmacologically active components, 
which are complexed to form a single molecule (e.g., sulfasalazine, Levodopa-
Entacapone). Soft drugs are the modified derivatives with predetermined metabo-
lism, so that after exerting pharmacological action for suitable time, its metabolite 
can be eliminated from body. Main aim of developing soft drugs is to avoid toxicity 
associated with formed metabolites. Hard drugs are opposite to soft drugs, where 
the modifications are made in such a way that its original properties are retained 
but are not prone to chemical or biological transformation to avoid generation of 
metabolites or to increase the biological activity.
Apart from abovementioned classification, there are two main broad classes of 
prodrug that are carrier-linked prodrug and bioprecursor prodrug. In carrier-linked 
prodrug, the drug is linked to a carrier moiety by a temporary covalent linkage. 
Cleavage of a carrier prodrug generates a molecular entity of increased bioactivity 
(drug) and at least one side product, the carrier, which may be biologically inert. 
Carrier molecule or functional group can be easily removed in vivo, usually by 
hydrolytic cleavage [3]. There are several criteria for being a carrier-linked prodrug, 
which are as follows:
• Link between drug and a carrier molecule must be a covalent linkage.
• Carrier-linked prodrug is inactive or less active than the parent compound.
• The linkage between the drug and the carrier molecule must be broken in vivo.
• The prodrug, as well as the in vivo released transport moiety, must be 
nontoxic.
• The generation of the active form must take place with rapid kinetics to ensure 
effective drug levels at the site of action and to minimize either alternative 
prodrug metabolism or gradual drug inactivation.
Bioprecursor prodrug results from a molecular modification of the active prin-
ciple. In vivo transformation of drug generates a new metabolite [4].
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Several goals of developing prodrug are as follows:
Improving unfavorable physical properties:
• Improvement in water solubility.
• Improvement in lipophilicity.
• Improvement in chemical stability.
• Improvement in organoleptic characteristic.
Improving unfavorable pharmacokinetic properties:
• Improving bioavailability.
• Improving penetration power through membrane.
• Improved first-pass metabolism.
• Target-specific drug delivery.
Classical example of target-specific drug delivery in selective metastatic colon 
cancer is capecitabine which is prodrug of 5-fluorouracil. Capecitabine requires triple-
phase transformation to be converted to its active form 5-fluorouracil. The first metabo-
lism takes place in liver by action of enzyme carbonyl esterase. This transformed form 
then enters the tumor cells by selective uptake and is again transformed by deamination 
by action of enzyme cytidine deaminase. This form in tumor cell is converted to 5-fluo-
rouracil by enzyme thymidine phosphorylase, which is only present in the tumor cells.
The other example of target-specific delivery is release of sulfasalazine in colon 
by action of bacterial reductase where sulfasalazine is converted to sulfapyridine 
and 5-amino salicylic, where the later formed is the active molecule.
One of the best ways to improve the lipophilicity is the esterification of the 
molecule. For example, terbutaline is orally active beta-2-agonist and is indicated 
in bronchial asthma. It requires significantly higher dose due to lower lipophilicity. 
Its prodrug bambuterol has improved lipophilicity as well as chemical stability and 
thus requires considerably lower dose than terbutaline [5].
3. Determination of chemical properties
Determination of chemical properties indicates the absorption behavior as well 
as stability of a molecule in the body. One of the most widely determined chemical 
properties includes partition coefficient (Log P), dissociation constant (pKa or 
pKb), and stability of molecule under a variety of conditions. Each property has 
significant value in development of formulation.
3.1 Partition coefficient
Partition coefficient (Log P) value is defined as ratio of unionized drug dis-
tributed between aqueous and organic phase. Oil-water partition coefficient gives 
the idea about drug’s ability to cross the lipidic membrane. Lipophilic/hydrophilic 
balance is one of the most important contributing factors for optimum drug 
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absorption and delivery. Due to lipidic nature of biological membrane, the amount 
of drug absorbed depends heavily on its lipophilicity. It is the unionized form of 
molecule that has better lipophilicity and hence it has received so much importance.
  Log P =  ( Coil ______ Cwater) equilibrium (1)
If the value of Log P is 0, it indicated that drug has equal distribution in water 
and partition solvent. Value of Log P less than 1 is indicative of higher water solubil-
ity and value greater than 1 is indicative of higher lipidic solubility. For optimum 
solubility and absorption, a proper hydrophilic-lipophilic balance is necessary.
Determination of Log P value in biological system is next to impossible task, so 
several methods are available to determine partition coefficient of molecule in vitro, 
which are as follows:
• Shake flask method
• Chromatographic method (HPLC)
• Computation based on software
• Countercurrent/filter probe method
Highly used method is shake flask method that utilizes octanol-water system to 
determine drug’s partitioning behaviors. There are several reasons behind selection 
of octanol as partitioning solvent, which can be explained as follows:
• Octanol is believed to mimic the lipoidal character of biological membrane as it 
contains polar head and nonpolar tail.
• Octanol is organic compound that is immiscible with water; however, some of 
the water is expected to be present in polar head portion.
• Solubility parameter for most of the drugs resembles with that of octanol.
3.2 Dissociation constant
Like partition coefficient, dissociation constant (pKa) is the property that deter-
mines the solubility in pH-dependent environment and extent of ionization. It is 
the extent of ionization that determines the absorption as only unionized form can 
be absorbed and hence it becomes essential to determine the pKa value of molecule. 
pKa value determination gives idea about site of absorption.
Weakly acidic drugs having pKa value around 4 are best absorbed from stomach 
as they are predominantly present in unionized form. Basic drugs having pKa value 
of around 8 are best absorbed from intestine as they are predominantly present in 
unionized form. % ionization can be determined by the following equation:
  %Ionization =  {  10 
 (pH−pKa)  __________ 
1 +  10  (pH−pKa)  } × 100 (2)
Most of the strong acids and strong bases are present in ionized form throughout 
GIT and hence poorly absorbed. But it is also true that most of the pharmaceutical enti-
ties are derivatives of weak acids and weak bases and hence absorption is not an issue.
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3.3 Chirality
One of the most silent chemical parameters that define the pharmacological 
activity is the type of isomer. Many molecular entities exist in racemic form, but 
only one form gives the desirable pharmacological activity. Other present isomer 
may be devoid of pharmacological activity or may exhibit deleterious side effects. 
Most of us are known to teratogenic tragedy of thalidomide. Thalidomide exists as 
racemic form. Racemates contain equal amount of enantiomer, which are known as 
either levorotatory (−) or dextrorotatory (+) based on its ability to rotate the plane 
of polarized light [6].
It was introduced as a sedative agent. The S-enantiomer of thalidomide was 
a teratogenic agent, while R-enantiomer was effective as a sedative agent. Lack 
of knowledge about chiral selectivity leads to disastrous consequence. In recent 
times, single enantiomer is dominating the market over the racemate form due 
to better pharmacological performance. Nowadays, racemic switching or chiral 
switching is used in which racemic mixtures are developed as single enantiomers. 
Several single enantiomers are preferred over racemic form (e.g., levofloxacin 
(ofloxacin), esomeprazole (omeprazole), escitalopram (citalopram), and deslo-
ratadine (loratadine)) [7].
Overview of the same is given in Table 1. For better clinical performance of 
the molecule, it has become necessity to study the chirality of the molecule. In 
most of the cases, it can be studied by optical rotatory dispersion and circular 
dichroism [8].
3.4 Stability of molecule
The main objective of determining stability of molecule is to identify the condi-
tions in which molecule is susceptible to deteriorate and to determine degradation 
pathway. The mechanism of degradation and condition provides the idea about 
proper designing of formulation, suitable molecular modification, appropriate 
storage condition, and selection of proper packaging material.
Drug in 
racemic form
Used active 
enantiomer
Advantage offered
Ofloxacin Levofloxacin
S(−)-enantiomer
Enhanced activity against pneumococci
Cetirizine Levocetirizine
R(−)-enantiomer
Less sedative action with same activity
Ketoprofen Dexketoprofen
S(+)-enantiomer
Reduction is dose of ketoprofen (half) with same effectiveness 
and lesser GT-related side effects
Ibuprofen S(+)-enantiomer (S)-ibuprofen is over 100-fold more potent inhibitor of 
cyclooxygenase. So three times dose reduction was achieved 
than racemic mixture
Omeprazole Esomeprazole
S(+)-enantiomer
Esomeprazole has lower first-pass metabolism and shows better 
bioavailability than R-eneantiomer and maintains pH above 4 in 
patients with GERD with least variability
Salbutamol Levalbuterol Racemic for and S-enantiomer hyperresponsiveness in 
sensitized patients with loss of bronchodilator activity. (R)-
salbutamol produces significantly greater bronchodilation than 
the equivalent dose of the racemate
Table 1. 
Advantage of racemic switching.
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The major mechanisms by which a molecule undergoes degradation are hydroly-
sis, oxidation, photolysis, and racemization. Out of these mechanisms, hydrolysis is 
perhaps the most studied after oxidation.
3.4.1 Hydrolysis
Hydrolysis involves reaction of a molecule with water resulting in cleavage of a 
chemical bond within the molecule. If readily hydrolyzable functional groups are 
available, then reaction proceeds even at faster rates, making the molecule ineffective. 
Molecules containing esters and amide functional groups are prone to hydrolysis and 
especially the ester derivatives, which may lead to formation of carboxylic acid or an 
alcohol.
• Effectiveness of molecule therefore depends on hydrolytic stability of mol-
ecule. For example, lidocaine is amide derivative of procaine, which is ester 
derivative used as local anesthetic. As ester derivative is more readily hydro-
lyzed; its duration of action is short while amide derivative is more stable and 
hence used as long-acting local anesthetic.
• Beta-lactam antibiotics are susceptible to hydrolysis and hence they are sup-
plied as dry powder injection where they are reconstituted before intravenous 
administration.
3.4.2 Oxidation
Many molecules can undergo oxidative degradation, which involves exposure of 
molecule to atmospheric oxygen or autoxidation by free radicals. However, in some 
cases, oxidation can be initiated in presence of light or elevated temperature. So 
degree of oxidation can be controlled by avoiding exposure to lights and storage at 
controlled temperatures. Even the extent of oxidation can be controlled by addition 
of antioxidants. The extent of oxidation for a given substance can be studied by 
passing oxygen through the solution of substance, or it can be achieved by addition 
of hydrogen peroxide to the solution of substance.
3.4.3 Photolysis
Photolysis refers to decomposition of a molecule by absorption of energy when 
exposed to light. Exposure to light not only brings photodegradation but may 
trigger oxidation. It is absorption of shorter wavelength components that may bring 
oxidation than longer wavelength components. Prior knowledge of photochemi-
cal behavior can provide guidance regarding storage condition, packaging, and 
handling condition. In most of the cases, the photochemical behavior of molecule 
is studied in the range of different spectral regions that are 200–290, 290–320, 
320–400, and 400–700 nm. For example, riboflavin and vitamin B12 are suscep-
tible to photodegradation directly and oxidation induced by light. So to avoid the 
decomposition, the formulation containing vitamin B12 and riboflavin is stored in 
amber color vials. Amber color bottles do not allow the ultraviolet radiation to pass 
through, which is the main factor for photodegradation [9].
3.4.4 Racemization
It is an event where optically active molecule becomes inactive without any change 
in molecular composition. Such study is of highest importance when racemic mixture 
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form is used. Racemization leads to either loss of pharmacological action or toxic 
effect may be enhanced by severalfold. Racemization is mostly affected by the condi-
tions like pH, type of solvents, presence of light, and temperature. So main goal in 
this study is to design optimum condition in which molecule can remain stable [10].
4. Physical characterization of molecule
Most often than not, new chemical entity exists in solid form and the properties 
under study during preformulation phase are bulk property characterization and 
micromeritic property characterization. Bulk property characterization includes 
study of polymorphism, crystallinity, density, nature of molecule like deliquescence 
or hygroscopicity and micromeritic characterization includes study of particle size, 
shape, porosity, and density. As most of the new chemical entities are solids, they 
exist either as amorphous or in crystalline state. Either of the form imparts the two 
main virtues that are stability and solubility.
4.1 Solubility
One of the most widely studied techniques during preformulation analysis is 
solubility profile of drug candidate. It is the backbone study of preformulation stage 
that determines the performance of developed formulation. Solubility and perme-
ability forms the scientific basis of biopharmaceutics classification system (BCS), 
which can provide framework for designing type of drug delivery system. Table 2  
provides basic idea about basic BCS classification and link between solubility, 
permeability, and type of targeted formulation.
The solubility of a drug is the amount of the drug that dissolves in a given sol-
vent to produce a saturated solution at constant temperature and pressure. Table 3  
provides outline of different levels of solubility. For conversion of drug molecule 
into an effective oral formulation, it must have good aqueous solubility for better 
absorption. Solubility is not an independent parameter but it relies on several prop-
erties like crystal characteristics, temperature, pH, complexation, and molecular 
structure. There are several techniques, which are available to improve the solubility 
of drug candidate, which are as follows:
• Chemical modification of drug
• Addition of cosolvent or surfactant
• Particle size reduction
• Hydrotropy
• Complexation
4.2 Crystalline vs amorphous form
Amorphous drugs have randomly arranged molecules or atoms in the molecular 
lattice. Typical amorphous forms are obtained by techniques like precipitation, rapid 
cooling after melting, and lyophilization. One of the most important advantages asso-
ciated with amorphous form is the higher solubility and hence the higher dissolution 
rate. More often than not drugs with low water solubility lead to poor bioavailability 
and variable clinical response. So, polymorphic form may overcome this problem 
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with main challenge of stability. The associated disadvantage is the reduced stability 
in comparison to crystalline form, so upon storage, amorphous forms tend to revert to 
more stable form. But the risk-to-benefit ratio remains in the favor of amorphous from 
and hence is more preferred for product development. For example, novobiocin when 
administered in crystalline form showed no therapeutic activity, while amorphous 
from showed better absorption from gastrointestinal tract with significant therapeutic 
response [11]. Crystalline form is characterized by regular spacing between molecular 
lattices in three-dimensional structure. One of the striking advantages associated with 
this form is the impeccable stability at a cost of lower water solubility than amorphous 
form. For example, Penicillin G as sodium or potassium salt in crystalline form has 
the better stability and hence stable and better therapeutic response in comparison 
to amorphous form. Various techniques are available to study crystallinity like X-ray, 
differential scanning microscopy, differential thermal analysis, hot stage microscopy, 
and the most important one that is scanning electron microscopy.
4.3 Polymorphism and pseudo polymorphism
Polymorphism is the ability of a compound to crystallize as more than one 
distinct chemically identical crystalline species with different internal lattices or 
crystal packing arrangement. Type of crystalline species generated depends on 
temperature, solvent, and time. Polymorphs are chemically same but mainly differ 
with respect to physical and pharmaceutical properties. As different types of 
polymorphs exhibit different types of solubility, stability, and therapeutic activity, 
it has become mandatory to have preliminary and exhaustive screening to iden-
tify all the polymorphic crystal forms for each drug. Similarly, chloramphenicol 
palmitate exists in three different polymorphic forms, namely, A, B, and C. Form 
Descriptive term Part of solvent required for one part of solute
Very soluble Less than 1
Freely soluble 1–10
Soluble 10–30
Sparingly soluble 30–100
Slightly soluble 100–1000
Very slightly soluble 1000–10,000
Practically insoluble or insoluble 10,000 or more
Table 3. 
Solubility description.
BCS 
class
Solubility Permeability Approaches in formulation development
Class 1 High High Conventional solid oral dosage form
Class 2 Low High Use techniques to improve surface area or improving 
solubility by addition of cosolvents or surfactants
Class 3 High Low Use of permeability enhances
Class 4 Low Low Use approaches of classes 2 and 3
Table 2. 
Correlation of solubility and permeability with BCS class and associated approach in formulation 
development.
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B has higher solubility and better dissolution profile, while form A is more stable 
one but low serum concentration was observed. During formulating suspension 
of an anthelmintic drug oxyclozanide, transformation of unstable polymorph to 
more stable leads to different crystal size and causes caking. In case of creams, 
crystal growth leads to gritty texture and incase of suppositories one can observe 
different melting behaviors and leads to formulation instability [12]. When 
solvent molecules are incorporated into structure of drug molecule, it is known as 
solvate. When water is incorporated as solvent in the structure, they are termed 
as hydrates. Pseudopolymorphs are the different crystal form of solvates. This 
phenomenon is also referred to as solvomorphism. For example, during synthesis 
of ethinylestradiol, crystallization of final product is achieved by using solvents 
like acetonitrile, chloroform, methanol, and water. As a result, four different 
solvates are generated. Differentiation of pseudopolymorphs can be studied by hot 
stage microscopy (melting behavior). True polymorphs melt slightly and form a 
globule, while pseudopolymorphs give bubble in the system due to generation of 
vapor or gas from entrapped solvent.
Two different types of polymorphs are well defined and are known as “monotropic 
polymorphs” and “enantiotropic polymorphs.” Monotropic polymorph can be revers-
ibly changed into another form by change in temperature and pressure and the latter 
involves one-time transition into another form. With respect to stability and solubility, 
again polymorphs can be classified as stable and metastable polymorphs. Stable poly-
morph is one of the most physically stable polymorphic forms and has highest melting 
point, lowest energy, and least aqueous solubility, while metastable polymorph refers 
to forms other than stable polymorph and has highest energy, low melting point, 
highest aqueous solubility, and hence shows better bioavailability. Metastable poly-
morphs have wider application in developing formulation but still only one-tenth of 
metastable forms are having practical use as they suffer from the stability issues [13].
4.4 Deliquescency vs hygroscopicity
Hygroscopicity can be defined as the capacity of a compound to absorb 
atmospheric moisture. Amount of moisture absorbed depends on atmospheric 
conditions and surface area. Deliquescent substance absorbs moisture to a greater 
extent and liquefies itself. The main reason behind study of this property is because 
changes in the moisture level can influence chemical stability, flowability, and 
compressibility to a greater extent.
In European pharmacopeia, hygroscopicity is described by four different classes 
after being stored at 25°C at relative humidity of 80% for 24 hours.
• Slightly hygroscopic: After abovementioned storage condition, if overall 
increase in weight is greater or equal to 0.2% but less than 2% w/w.
• Hygroscopic: After abovementioned storage condition, if overall increase in 
weight is greater or equal to 0.2% but less than 15% w/w.
• Very hygroscopic: After abovementioned storage condition, if overall increase 
in weight is greater than 15% w/w.
For this study, samples under analysis are exposed to range of controlled relative 
humidity prepared with saturated aqueous salt solutions (Table 4). One can link 
flowability and relative humidity by amount of moisture uptake (Table 5).
Moisture level uptake can be monitored by techniques like thermogravimetric 
analysis (TGA), Karl Fischer titration, and gas chromatography.
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4.5 Particle size
Particle size greatly affects a number of quality parameters like dissolution rate, 
solubility, bioavailability, content uniformity, and lack of grittiness. Application of 
particle size study during preformulation stage is described as follows:
• When solubility is major issue, one may significantly improve the solubility by 
reducing the particle size (increased surface area).
• In case of suspension, particle size is the most important parameter, which 
determines the stability and quality of formulation. Too much reduction in the 
particle size leads to generation of charged particle and hence unstable system. 
On other hand, larger particle size leads to caking.
• Due to nonuniform particle size distribution, there is significant risk associ-
ated with content uniformity in case of potent formulations.
A number of methods are available to determine particle size, which are as 
follows:
• Microscopy
• Sedimentation rate
• Coulter counter method
• Surface area determination by nitrogen adsorption method
Apart from particle size, particle shape plays an important role during prefor-
mulation phase as the shape of particle may influence surface area, flow properties, 
and compaction force. A drug particle may exist in different forms like spherical, 
Process Affected properties
Precipitation Surface area, particle size, shape
Encapsulation Particle shape and size
Crystallization Particle shape, size, crystalline/amorphous nature
Chemical reaction Surface area and particle shape
Table 5. 
Use of different process to control particle size, shape, and surface area.
Substance used % RH achieved
Silica gel 0%
Potassium acetate 20%
Calcium chloride 30%
Potassium bromide 85%
Water 100%
Table 4. 
Utilization of different salts to give environment with different RH.
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angular, acicular, needle, oval, or rough. It is a well-accepted fact that a spherical 
particle has the maximum area and uniform flow property. The maximum surface 
area ensures the better solubility. For topical products that are working as abrasives, 
irregular particle shape is more preferred. Table 3 provides idea about various 
methods, which can control particle shape and size and provide better results 
needed to design a formulation.
4.6 Density and porosity
Density can be defined as ratio of mass of a substance to its volume, which 
greatly depends on particle size distribution and shape. The main problem arises 
during determination of bulk volume is the voids, which can be interparticulate, 
open, and closed intraparticulate. So by considering the presence of different types 
of void volume, various densities are proposed.
• True density: It is defined as total volume of solids excluding all space 
greater than molecule diameter. True density can be measured with helium 
pycnometer.
• Bulk density: It is defined as total volume occupied by entire powder mass. It 
can be determined by placing previously sieved powder bulk into a graduated 
cylinder and measuring the volume in milliliters. Division of original weight 
and attended volume gives idea about bulk density.
• Tapped density: It is determined by placing graduated cylinder containing 
known weight of sample on tapped density apparatus and is operated for the 
fixed number of taps until a constant volume is attained. Ratio of total amount 
of substance taken to the final constant volume gives idea about tapped density.
One needs to gain knowledge about the size and type of dosage form and is the 
most critical parameter for the low potency drugs. In most of the cases, two types of 
density are studied, namely, bulk density and tapped density.
Following problems can be addressed related to density:
• With drugs having low density, the bulk becomes more and hence capsule 
formulation is quite difficult to formulate as capsule can incorporate limited 
volume.
• In development of tablet formulation, low-density drug creates difficulties 
as they are having low compressibility and hardness in tablet is difficult to 
achieve.
• If the difference of density is more between drug substances and excipient 
is more, homogeneity in the formulation is difficult to achieve.
4.7 Flow properties
Flow property of material can be affected by a number of factors including 
frictional forces, surface tension forces, electric forces, and van der Waals forces.
Efficient flow of drug substance powder is needed for effective tablet formula-
tion. The main reason behind inclusion of this parameter in preformulation is its 
linkage with other physical parameters like hygroscopicity and particle size and 
shape. Importance of flow property is even more when dose loading is more.  
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Table 6 gives outline on correlation of flow properties of a material with moisture 
uptake at different humidity levels.
• In case of hygroscopic material, flow property of drug tends to deteriorate as 
the presence of absorbed moisture increases cohesiveness.
• Irregular particle size and nonuniform shape can also disturb normal flow 
property of drug.
Normally, flow property of solid drug substance can be measured by Hausner ratio, 
Carr’s index, and angle of repose, and in case of liquids or semisolid, rheology and 
thixotropy. Carr’s compressibility index can be represented by the following formula.
  Carr � s compressibility index =  
Tapped density − Bulk density
   _______________________ 
Tapped density
 × 100. (3)
Hausner’s ratio can be represented by the following equation:
  Hausner � s ratio =  
Tapped density
  ____________
Bulk density
 . (4)
Table 7 provides the correlation between Carr’s index, Hausner’s ratio, and 
flowability.
Another way of measuring flow property is angle of repose, which provides the 
idea resistance to the movement of particle. It can be represented by the following 
formula:
  tan θ = 2h / D (5)
Carr’s index Hausner’s ratio Flowability
5–15 1.05–1.18 Excellent
12–16 1.14–1.20 Good
18–21 1.22–1.26 Fair-passable
23–35 1.30–1.54 Poor
33–38 1.50–1.61 Very poor
Greater than 40 Greater than 1.67 Very very poor
Table 7. 
Correlation between Carr’s index, Hausner’s ration, and flowability.
Relative humidity (%) Moisture uptake (%) Flowability
1 0.30 Free flowing
10 0.24 Free flowing
20 0.27 Less free flowing
40 0.35 Base of powder adheres to the container
80 0.62 Cake formation
Table 6. 
Correlation between relative humidity, moisture uptake, and flowability.
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It is the maximum angle that can be obtained between height of pile and a hori-
zontal plane. It gives a brief idea about internal cohesive and frictional levels. There 
are basically two types of methods that are available, which are as follows:
Static angle of repose
1. Fixed funnel method
2. Fixed cone method
Dynamic angle of repose
1. Rotating cylinder method
2. Tilting box method
5. Drug excipient compatibility
Excipients are added along with the active pharmaceutical ingredient in formu-
lations. Most excipients possess biological activity but having role in administra-
tion, mediating the release of the active component, and providing stability against 
degradation. However, inappropriate excipients can also give rise to inadvertent 
and/or unintended effects, which can affect the chemical nature, the stability, and 
the bioavailability of the API, and consequently, their therapeutic efficacy and 
safety. So study about interaction between active ingredient and inactive ingredi-
ent can provide idea about type of incompatibility and the justification behind the 
inactive ingredient selection [14].
• Change in organoleptic properties of formulation.
• Changes in in vivo performance of formulation, that is, dissolution.
• Decreased potency of active ingredient.
• Generation of toxic degradation product.
• Change in physical appearance of formulation, that is, color, phase conversion.
In general, one can say that drug-excipient incompatibility may result in change in 
physical, chemical, microbiological, or therapeutic properties of formulation.
5.1 Physical incompatibility
In such an instance, active pharmaceutical ingredient and excipients interact 
without undergoing changes involving like breaking or formation of new bonds. 
The resulting drug product retains its original chemical properties but may involve 
changes such as alteration in physical properties. Such interaction results in changes 
like change in color, odor, flow properties, and sedimentation rate. Such an example 
of physical incompatibility is between tetracycline and calcium carbonate. It results 
in formation of insoluble complex with calcium carbonate, leading to slower dis-
solution and decreased absorption in the gastrointestinal tract [15].
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5.2 Chemical incompatibility
In such incompatibility, there is interaction of active pharmaceutical ingredi-
ent and excipient through chemical degradation pathway. The chemical reaction 
involves bond breakage or new bond formation to produce an unstable chemical 
entity. Chemical reaction may take place as hydrolysis, oxidation racemization, 
and Maillard reactions. The resulting changes are more deleterious than physical 
incompatibility. This type of incompatibility can be assessed by chromatographic 
studies. One of the classical examples of chemical incompatibility is exhibited by 
reaction of lactose with amino group of active pharmaceutical ingredient referred to 
as “Maillard reaction” and results into darkening of formulation with characteristic 
odor. Classical example is of a bronchodilator aminophylline, in which ethylenedi-
amine moiety is reduced by lactose and as a result brown discoloration appeared in 
samples containing 1:5 (w/w) mixtures of aminophylline and lactose after storing at 
60°C for 3 weeks [16].
5.3 Therapeutic incompatibility
Such interaction is also referred to as biopharmaceutical interaction, but it 
differs from previously discussed incompatibilities in a way that interaction will 
take place once the formulation is administered into the body. Such type of incom-
patibility is associated with alteration in drug absorption in the body. In other way, 
one can say that interaction is taking place between excipient, active component, 
and physiological fluid. One of the classical examples of such incompatibility is 
interaction of enteric coated polymers, when administered along with antacids. In 
such an event, they dissolve prematurely and release the drug that is liable to acid 
degradation or may cause adverse effect in GI, that is, gastric bleeding associated 
with NSAIDs [17].
There are specific methods that are employed to determine the existence of 
incompatibility between excipient and the active pharmaceutical ingredient. Out 
of all analytical techniques, thermal methods of analysis can provide most positive 
outcome. In association with thermal methods of analysis, spectroscopic techniques 
like X-ray diffraction and infrared spectroscopy can provide sideline assistance. 
High-performance liquid chromatography and thin-layer chromatography provide 
the more suitable way of studying chemical incompatibilities and provide qualita-
tive and quantitative assessments.
6. Conclusion
It can be concluded that preformulation is a proactive phase that deals with 
transformation of new chemical entity into a safe, effective, and most importantly 
stable pharmaceutical formulation.
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